Ph I/II of GOS in acute GVHD (Stem Cell Transplantation)

Ph I/II of GOS in acute GVHD (Stem Cell Transplantation)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to see if taking a prebiotic (dietary supplement) can reduce the risk of acute graft-versus-host disease (a common complication) in people who receive an allogeneic stem cell transplant. This study is important because prebiotics are a common and safe dietary supplement, and there is a need for a safe and effective way to reduce graft-versus-host disease after transplant.

Who Can Participate?

Eligibility

Adults ages 18-80 who:
  • Are scheduled to get an allogeneic stem cell transplant for any type of illness
  • Are able to read and write in English
  • Are not pregnant or nursing
  • Do not have any disease or condition affecting their digestive tract
  • Are not using any prebiotic, probiotic, or antibiotic
For more information about who can join this study, please contact the study team at andrea.pires@duke.edu or 919-668-4978.

Age Range

18-80

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join the study, you will:
  • Be randomly asssigned (like a coin flip) to receive the prebiotic (food additive that affects gut bacteria) or a placebo (food additive that does not affect gut bacteria)
  • Give stool samples
  • Have your skin swabbed
  • Have blood draws
  • Fill out questionnaires
  • Have Cardiopulmonary Exercise Testing (CPET) done
  • Have complete body composition testing done
  • Have muscle and fat composition testing done using a hand-held ultrasound device
  • Complete physical function and cognitive function assessments

Locations

Duke University Hospital
Other

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

IIT: A Phase I/II Trial of the prebiotic galacto-oligosaccharide to prevent Acute GVHD

Principal Investigator

Mitchell
Horwitz

Protocol Number

PRO00105137

NCT ID

NCT04373057

Phase

N/A

Enrollment Status

Open to Enrollment